Evaluating the therapeutic effect of tumor treating fields (TTFields) by monitoring the impedance across TTFields electrode arrays.
Brain tumor
Impedance detection
Monitoring sensitivity
Tumor Treating Fields
Tumor condition
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
09
2021
accepted:
12
01
2022
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Tumor Treating Fields (TTFields), are a novel, non-invasive tissue ablation technology for treatment of cancer. Tissue ablation is achieved through the continuous delivery of a narrow range of electromagnetic fields across a tumor, for a period of months. TTFields are designed to affect only cells that divide and to interfere with the cell division process. The therapy is monitored with MRI imaging, performed every couple of months. Current technology is unable to assess the treatment effectiveness in real time. We propose that the effect of the treatment can be assessed, in real time, by continuously measuring the change in electrical impedance across the TTFields delivery electrode arrays. An Experiments show that measuring the change in the impedance amplitude between opposite TTFields electrode arrays, at a typical TTFields treatment frequency of (200 kHz), can detect changes in the tumor radius with a sensitivity that increases with the radius of the tumor. The study shows that TTFields electrode arrays can be used to assess the effectiveness of TTFields treatment on changes in the tumor dimensions in real time, throughout the treatement. This monitoring system may become a valuable addition to the TTFields cancer treatment technology. It could provide the means to continuously assess the effectiveness of the treatment, and thereby optimize the design of the treatment protocol.
Sections du résumé
BACKGROUND
Tumor Treating Fields (TTFields), are a novel, non-invasive tissue ablation technology for treatment of cancer. Tissue ablation is achieved through the continuous delivery of a narrow range of electromagnetic fields across a tumor, for a period of months. TTFields are designed to affect only cells that divide and to interfere with the cell division process. The therapy is monitored with MRI imaging, performed every couple of months. Current technology is unable to assess the treatment effectiveness in real time.
METHODS
We propose that the effect of the treatment can be assessed, in real time, by continuously measuring the change in electrical impedance across the TTFields delivery electrode arrays. An
RESULTS
Experiments show that measuring the change in the impedance amplitude between opposite TTFields electrode arrays, at a typical TTFields treatment frequency of (200 kHz), can detect changes in the tumor radius with a sensitivity that increases with the radius of the tumor. The study shows that TTFields electrode arrays can be used to assess the effectiveness of TTFields treatment on changes in the tumor dimensions in real time, throughout the treatement. This monitoring system may become a valuable addition to the TTFields cancer treatment technology. It could provide the means to continuously assess the effectiveness of the treatment, and thereby optimize the design of the treatment protocol.
Identifiants
pubmed: 35186474
doi: 10.7717/peerj.12877
pii: 12877
pmc: PMC8833244
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e12877Informations de copyright
©2022 Li et al.
Déclaration de conflit d'intérêts
Boris Rubinsky is an Academic Editor for PeerJ. The other co-authors declare that they have no competing interests.
Références
Sci Rep. 2016 Feb 22;6:21667
pubmed: 26898944
IEEE Trans Biomed Eng. 2020 Sep;67(9):2594-2602
pubmed: 31940516
Crit Rev Biomed Eng. 1989;17(1):25-104
pubmed: 2651001
PLoS One. 2013 May 14;8(5):e63223
pubmed: 23691001
Cancers (Basel). 2019 Feb 02;11(2):
pubmed: 30717372
J Neurointerv Surg. 2018 Nov;10(11):1079-1084
pubmed: 29511114
Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13
pubmed: 25213869
PLoS One. 2017 Jun 12;12(6):e0179214
pubmed: 28604803
Sci Rep. 2015 Dec 11;5:18046
pubmed: 26658786
Physiol Meas. 2006 Sep;27(9):829-38
pubmed: 16868349
PLoS One. 2013 Nov 06;8(11):e77089
pubmed: 24223118
Physiol Meas. 2009 Aug;30(8):809-19
pubmed: 19567939
Physiol Meas. 2006 Jun;27(6):539-52
pubmed: 16603802
Physiol Meas. 1995 Aug;16(3 Suppl A):A99-109
pubmed: 8528131
Radiat Oncol. 2020 Apr 19;15(1):83
pubmed: 32307022
CNS Oncol. 2017 Jan;6(1):29-43
pubmed: 27628854
Mater Sci Eng C Mater Biol Appl. 2012 Dec 1;32(8):2664-2667
pubmed: 23139442
Neuro Oncol. 2016 Oct;18(10):1338-49
pubmed: 27664860
IEEE Trans Biomed Eng. 2007 May;54(5):953-6
pubmed: 17518296
Cancer Res. 2004 May 1;64(9):3288-95
pubmed: 15126372
Ann Neurosci. 2013 Jul;20(3):99-107
pubmed: 25206025
Clin Cancer Res. 2018 Jan 15;24(2):266-275
pubmed: 28765323
Ann Biomed Eng. 2019 Mar;47(3):706-713
pubmed: 30610409
Neurocrit Care. 2018 Feb;28(1):117-126
pubmed: 28547320
Ann N Y Acad Sci. 2013 Jul;1291:86-95
pubmed: 23659608